Association of toll-like receptor 4, 5 and 10 polymorphisms with *Helicobacter pylori*-positive peptic ulcer disease in a center in Jordan

Laith AL-Eitan, Fouad Abdelaziz Almomani, Sohaib Mahmoud Al-Khatib, Hanan Abdulraheem Aljamal, Mohammed Nayef Al-Qusami, Rawn Abdulraheem Aljamal

From the Department of Biotechnology and Genetic Engineering, Jordan University of Science and Technology, Irbid, Jordan

**BACKGROUND:** Helicobacter pylori infection is widespread, affecting about 50% of the global population. Polymorphisms in host genes such as the toll-like receptor 4 (TLR4) might affect the susceptibility and severity of infection and treatment success.

**OBJECTIVE:** Investigate the susceptibility and severity of *H. pylori* infection with host TLR4 (rs11536889, rs4986790, rs200109652, rs10759932), TLR5 (rs5744174, rs2072493, rs746250566), TLR10 (rs559182335, rs10004195) polymorphisms.

**DESIGN:** Analytical, cross-sectional.

**SETTING:** Endoscopy clinic at tertiary care center.

**PATIENTS AND METHODS:** Genomic DNA was extracted from formalin-fixed paraffin-embedded tissues collected from *H. pylori*-infected patients and healthy individuals. The single nucleotide polymorphisms (SNPs) within the targeted TLR genes were genotyped to assess the genetic association of various SNPs with disease severity.

**MAIN OUTCOME MEASURES:** Effect of genotype distribution on *H. pylori* infection.

**SAMPLE SIZE:** 250 peptic ulcer patients and 217 controls.

**RESULTS:** The TLR10 genotype showed no significant association with *H. pylori* infection except for rs10004195 (T>A) (P=.002). The genotype frequency of Rs5744174 in TLR5 had a significant association with the presence of *H. pylori* infection (P=.046, OR=0.52). Except for gender (P=.022), there were no significant associations between clinical and demographic variables and SNPs relating to the severity of the *H. pylori* infections.

**CONCLUSIONS:** Our findings are consistent with differences in severity of *H. pylori* infection due to TLR SNPs in different ethnic groups. Understanding differences in genetic susceptibility could help in classifying patients and matching patients with various treatment options on a genetic basis.

**LIMITATIONS:** Lack of *H. pylori* pathogenicity features assessment.

**CONFLICT OF INTEREST:** None.
**H pylori Infection**

Helicobacter pylori is one of the most common pathogenic bacteria that colonizes the stomach of approximately 50% of the population worldwide.\(^1\)\(^-\)\(^3\) H pylori infection is a global issue associated with a variety of gastric diseases ranging from chronic gastritis, peptic ulcer disease (PUD), gastric lymphoma, gastric cancer to multiple extraintestinal diseases.\(^4\)\(^-\)\(^11\) The risk and severity of H pylori infection is influenced by many factors including the host, environmental conditions, strain-specific virulence factors, diet, high salt intake, smoking, host response genes, genetic polymorphisms, and genetic susceptibility.\(^5\)\(^-\)\(^8\)\(^,\)\(^12\) The epithelial cells of the gastric mucosa are the first line of defense of innate immunity against H pylori infection.\(^13\) The pathogen recognition receptors (PRRs), which recognize various bacterial molecular patterns, play a major role in the stimulation of adaptive immunity.\(^11\) The presence of infecting microorganisms such as H pylori in the gastrointestinal tract is sensed by toll-like receptors (TLRs) that belong to the PRR family.\(^15\)\(^,\)\(^16\) H pylori infection is followed by activation of neutrophils and mononuclear cells, which leads to the stimulation of genes involved in the host response. These genes include those encoding antigen-presenting molecules, regulatory cytokines (IL-10), inflammatory cytokines (TNF-α, IL-1, IL-6, and IL-8), and costimulatory molecules that elicit the adaptive immune response.\(^17\)\(^,\)\(^18\)

Chronic inflammation can be caused by the long-term presence of H pylori colonization of the gastric epithelium.\(^19\) Therefore, an increased immune response, which may eventually lead to an ulcer, can be a precursor of gastric cancer if not controlled.\(^20\) Thus, after weighing the evidence, it is certain that the study of TLR function as an H pylori receptor on the surface of gastric epithelial cells is highly important.\(^16\)\(^,\)\(^21\) The impaired activity of these receptors could be involved in an impaired response, damage of related-tissue, infectious diseases, and autoimmunity.\(^14\) Previous studies have demonstrated the association of polymorphisms in TLRs genes including TLR1, TLR2, TLR6, and TLR10 with increased levels of anti-H pylori antibodies generated via TLR and associated with the severity of intestinal metaplasia linked to H pylori infection.\(^5\)\(^,\)\(^9\)\(^-\)\(^22\) Therefore, the objective of this study was to examine the association of certain TLR gene polymorphisms with the presence of H pylori infection (susceptibility and severity) in the Jordanian population.

**METHODS**

**Patients recruitment and selection**

Participants were all Jordanians older than 18 years who visited the endoscopy clinic for a gastroscopic examination at King Abdullah University Hospital (KAUH), Ramtha, Jordan. A total of 640 formalin-fixed, paraffin-embedded (FFPE) gastric tissue biopsies were collected by the cytology laboratory at KAUH between 2017 and 2018. Of the 468 samples that fulfilled the inclusion criteria, 251 were H pylori positive patients with PUD; 217 H pylori negative patients were used as control subjects (Figure 1). Demographic data was collected based on a structured questionnaire, while the clinical history was collected from medical records. Patients were eligible for inclusion in the study if they were Jordanian and had a confirmed H pylori infection using gastric antrum biopsy samples by a specialized physician following gastroscopic examination. Eligible patients had no history of gastric surgery. Patients were classified according to the Updated Sydney Classification on H pylori chronic gastritis into two groups (active/acute and inactive/chronic) based on the presence of mononuclear cells in the histopathological analysis.\(^23\) Moreover, the severity of H pylori infection was categorized based on the number of mononuclear cells into three categories (mild, moderate, and severe).\(^21\) Ethical approval was obtained from the Institutional Review Board (IRB) committee at the Jordan University of Science and Technology (no. 15/105/2017).

**DNA analysis**

The genomic DNA was extracted from FFPE tissue collected from the patients who visited the endoscopy clinics using the commercially available kit, DNeasy Blood & Tissue Kit (Qiagen Ltd., West Sussex, UK). The concentration and purity of extracted DNA was assessed using a NanoDrop 1000 spectrophotometer. The pure DNA samples with their concentrations were sent to the Australian Genome Research Facility (AGRF, Melbourne Node, Melbourne, Australia) for genotyping of TLR4 (rs11536889, rs4986790, rs200109652, and rs10759932), TLR5 (rs5744174, rs2072493, and rs746250566), and TLR10 (rs559182335, and rs10004195) using the Sequenom MassARRAY system (iPLEX GOLD) (Sequenom, San Diego, CA, United States).

**Statistical analysis**

Genotypic, allelic, and clinical data association was performed using IBM SPSS version 25.0 (IBM Corp. Armonk, NY). The distribution of the studied single nucleotide polymorphisms (SNPs) in patients and controls and the association of these polymorphisms with the severity and activity of H pylori infection was tested using...
the chi-square test. The Hardy-Weinberg equilibrium (HWE) values for genotype distribution and minor allele frequency (MAF) was calculated using the SNPStats Web Tool (https://www.snpstats.net/start.htm).

RESULTS
The 468 DNA samples consisted of 217 controls and 250 PUD patients. The median (interquartile range) age of patients and controls were 41 (23.8) and 53 (30), respectively. Overall, there were 98 females (45.2%) and 119 males (54.8%).

About half of the H pylori-positive patients (45.2%) had moderate H pylori infection, 26.7% had mild infection, 17.1% had severe infection, and 10.7% had inactive H pylori infection (Table 1). Other clinical and demographic characteristics did not differ except for infection activity between males and females (P=.022).

Five SNPs were in Hardy-Weinberg equilibrium and normally distributed (rs11536889, rs4986790, rs2072493, and rs746250566), while the other three SNPs (rs10759932, rs5744174, and rs10004195) were not in HWE (P<.05) (Table 2). The presence of selection, mutation, migration, and genetic drift mechanisms will affect allele frequencies, indicating that evolution has occurred in a population; this is reflected by violations of HWE assumptions. The last two SNPs, rs200109652 and rs559182335, are monomorphic SNPs.

For the TLR4 gene, there were no significant differences in the distributions of the polymorphisms between the patients and controls (Table 3). For the TLR10 gene, allele T has emerged as a risk factor for PUD, with the homozygous TT and heterozygous AT genotypes of the rs10004195, which were significantly abundant in the patients over the A allele in all genetic models (P=.019, .063, .0056, and .002). If PUD patients carry the AA genotype they have a decreased risk of PUD (OR= 0.34 and P=.019). Moreover, the rs5744174/TLR5 heterozygous GA genotype seems to increase the risk of PUD development. The genotype distribution of the variants based on the activity and severity of H pylori infection lack any statistically significant associations (Tables 4 and 5, respectively).

DISCUSSION
H pylori infection is worldwide spread, especially in developing countries. Once acquired, the infection...
Table 1. Clinical and demographic characteristics of Jordanian patients with peptic ulcer disease (n=250).

| Clinical Data          | Infection activity | P value |
|------------------------|--------------------|---------|
|                        | Mild   | Moderate | Severe | Inactive infection |
| Total                  | 67 (26.7) | 113 (45.0) | 43 (17.1) | 27 (10.7) |
| Age (years)            | 42 (25.5) | 39 (18) | 47 (28.5) | 34 (27.5) | .301 |
| Marital status         |        |         |         |         |
| Single                 | 19 (7.6) | 32 (13.2) | 6 (2.4) | 4 (1.6) | .16 |
| Married                | 48 (19.2) | 79 (31.9) | 36 (14.4) | 17 (6.8) |
| Divorced               | 0 | 1 (0.4) | 0 | 0 |
| Widowed                | 0 | 0 | 1 (0.4) | 0 |
| Gender                 |        |         |         |         |
| Male                   | 33 (13.2) | 57 (22.8) | 13 (5.2) | 7 (2.8) | .022 |
| Female                 | 34 (13.6) | 56 (22.4) | 30 (12.0) | 20 (8.0) |
| Other diseases         |        |         |         |         |
| No                     | 36 (14.4) | 73 (29.2) | 2 (8.4) | 14 (5.6) | .23 |
| Yes                    | 31 (12.4) | 40 (16.0) | 22 (8.8) | 13 (5.2) |
| Duodenal ulcer         |        |         |         |         |
| No                     | 58 (23.2) | 94 (37.6) | 37 (14.8) | 25 (10.0) | .67 |
| Yes                    | 9 (3.6) | 19 (7.6) | 6 (2.4) | 2 (0.8) |
| Esophagitis            |        |         |         |         |
| No                     | 55 (22.0) | 90 (36.0) | 37 (14.8) | 22 (8.8) | .85 |
| Yes                    | 12 (4.8) | 23 (9.2) | 6 (2.4) | 5 (2.0) |
| Epigastric pain        |        |         |         |         |
| Yes                    | 28 (11.2) | 53 (21.2) | 17 (6.8) | 15 (6.0) | .49 |
| No                     | 39 (15.6) | 60 (24.0) | 26 (10.4) | 12 (4.8) |
| Chronicity             |        |         |         |         |
| Yes                    | 67 (26.2) | 113 (45.2) | 43 (17.2) | 25 (10.0) | .16 |
| No                     | 0 | 0 | 0 | 0 |
| Proton-pump inhibitors |        |         |         |         |
| No                     | 0 | 5 (2.0) | 1 (0.4) | 2 (0.8) |
| Lansoprazole           | 50 (20.0) | 80 (32.0) | 31 (12.4) | 21 (8.4) |
| Esomeprazole           | 2 (0.8) | 0 | 0 | 1 (0.4) | .21 |
| Omeprazole             | 1 (0.7) | 1 (0.4) | 0 | 0 |
| Two or three           | 14 (0.6) | 27 (10.8) | 11 (4.4) | 3 (1.2) |
| Antibiotics            |        |         |         |         |
| No                     | 17 (7.6) | 26 (10.4) | 9 (3.6) | 6 (2.4) |
| Amoxicillin            | 3 (1.2) | 2 (0.8) | 1 (0.4) | 1 (0.4) |
| Clarithromycin         | 1 (0.4) | 3 (1.2) | 1 (0.4) | 0 | .81 |
| Amox+Clarith           | 44 (17.6) | 80 (32.0) | 30 (12.0) | 8 (7.2) |
| Others                 | 0 | 2 (0.8) | 2 (0.8) | 2 (0.8) |

Numbers are n (%), median (interquartile range) for age. Totals may not add to 100% because of missing data on some variables.
H pylori infection persists for life if not treated. To the best of the authors’ knowledge, there are a limited number of studies on the association between TLR polymorphisms and PUD in countries of the Middle East, especially in the Jordanian population. The study explores possible interactions of certain genetic polymorphisms in TLR4, TLR5, and TLR10 with the risk of H pylori infection, in addition to the severity of the disease.

TLR4 was the first TLR identified in humans associated with the recognition of bacterial lipopolysaccharides (LPS, an essential component of the gram-negative bacteria outer membrane). Several studies indicated that TLR variants might decrease the responsiveness to the gram-negative bacteria LPS due to alterations in the binding site, and thus influence the clinical outcome of H pylori. This could provide a plausible mechanistic explanation for different outcomes in H pylori-positive individuals. The results of this study revealed no association with susceptibility to H pylori infection (The degree to which individuals are liable to

### Table 2. Minor allele frequencies and the Hardy-Weinberg equilibrium P values of candidate polymorphisms for patients and controls.

| Gene   | Chromosomal location | rs numbers     | Minor allele | Patients (n=223) | Controls (n=217) | Odds ratio (95% CI) | P value |
|--------|----------------------|----------------|--------------|----------------|----------------|---------------------|---------|
| TLR4   | 9q33.1               | rs11536889     | C            | .1            | .09            | .061                |         |
|        | rs4986790            | G              | .01          | .999          | .02            | .999                |         |
|        | rs200109652          | C              | 1            | NA            | 1              | NA                  |         |
| TLR5   | 1q41                 | rs10759932     | C            | .16           | .16            | .02                 |         |
|        | rs5744174            | G              | .38          | <.0001        | .4             | .011                |         |
|        | rs2072493            | C              | .1           | .61           | .08            | .999                |         |
| TLR10  | 4p14                 | rs746250566    | A            | 0             | 1              | .999                |         |
|        | rs559182335          | T              | 1            | NA            | 1              | NA                  |         |
|        | rs10004195           | A              | .07          | <.0001        | .15            | <.0001              |         |

HWE: Hardy-Weinberg equilibrium

### Table 3. Distribution of the genotypes and alleles among cases and controls.

| Gene/SNP/Alleles | Patients (n=223) | Controls (n=217) | Odds ratio (95% CI) | P value |
|------------------|------------------|------------------|---------------------|---------|
| TLR4 (rs11536889)|                  |                  |                     |         |
| GG/GC/CC         | 79.8/19.8/0.4    | 84.2/13.9/1.9    | 1/1.5 / .23         | .083    |
| GG/GC + CC       | 79.8/20.2        | 84.2/15.8        | 1/1.35              | .23     |
| GG + GC/CC       | 99.6/0.4         | 98.1/1.9         | 1.021               | .12     |
| GG + CC/GC       | 80.2/19.8        | 86.1/13.9        | 1/1.53              | .096    |
| C                 | 10               | 9                | 0.874               |         |
| G                 | 90               | 91               | 1.014               | .516    |
| TLR4 (rs4986790) |                  |                  |                     |         |
| AA/AG            | 98.3/1.7         | 96.4/3.4         | 1/0.5               | .26     |
| A                 | 99               | 98               | 0.992               | .264    |
| G                 | 1                | 2                | 1.973               |         |
| TLR4 (rs20010965)|                  |                  |                     |         |
| CC                | 100              | 100              | NA                  | NA      |
| C                 | 100              | 100              | NA                  | NA      |
### Table 3 (cont.). Distribution of the genotypes and alleles among cases and controls.

| Gene/SNP/Alleles | Patients (n=223) | Controls (n=217) | Odds ratio (95% CI) | P value |
|------------------|------------------|------------------|---------------------|---------|
| **TLR4 (rs10759932)** |                  |                  |                     |         |
| TT/TC/CC         | 76.1/18.6/5.3    | 73.6/21.2/5.2    | 1/0.85/0.99         | .79     |
| TT/TC + CC       | 76.1/23.9        | 73.6/26.4        | 1/0.87              | .55     |
| TT + TC/CC       | 94.7/5.3         | 94.8/5.2         | 1/1.03              | .95     |
| TT + CC/TC       | 81.4/18.6        | 78.8/21.2        | 1/0.85              | .5      |
| C                | 15               | 16               | 1.082               |         |
| T                | 85               | 84               | 0.986               | .629    |
| **TLR5 (rs5744174)** |                  |                  |                     |         |
| GG/GA/AA         | 30.5/63.2/6.3    | 32.9/54.1/12.9   | 1/1.26/0.52         | .046    |
| GG/GA + AA       | 30.5/69.5        | 32.9/67.1        | 1/1.12              | .61     |
| GG + GA/AA       | 93.7/6.3         | 87.1/12.9        | 1/0.45              | .024    |
| GG + AA/GA       | 36.8/63.2        | 45.9/54.1        | 1/1.46              | .069    |
| A                | 62               | 60               | 0.969               |         |
| G                | 38               | 40               | 1.051               | .582    |
| **TLR5 (rs2072493)** |                  |                  |                     |         |
| TT/TC/CC         | 81.1/18.0/0.9    | 84.3/15.7/0      | 1/1.19/NA           | .28     |
| TT/TC + CC       | 81.1/18.9        | 84.3/15.7        | 1/1.25              | .39     |
| TT + TC/CC       | 99.1/0.9         | 100/0.0          | 1/NA                | .11     |
| TT + CC/TC       | 82.18/18.9       | 84.3/15.7        | 1/1.18              | .53     |
| C                | 10               | 8                | 0.795               |         |
| T                | 90               | 92               | 1.023               | .302    |
| **TLR5 (rs74625056)** |                  |                  |                     |         |
| GG/GA            | 100/0.0          | 99.5/0.5         | 1/0.0               | .21     |
| A                | 0                | 0.5              | NA                  |         |
| G                | 100              | 99.5             | 0.998               | .28     |
| **TLR10 (rs55918233)** |                 |                  |                     |         |
| TT               | 100              | 100              | NA                  | NA      |
| T                | 100              | 100              | NA                  | NA      |
| **TLR10 (rs10004195)** |                 |                  |                     |         |
| TT/AT/AA         | 90.5/4.7/4.7     | 84.3/13.1/3.1    | 1/1.42/0.34         | .019    |
| TT/AT + AA       | 90.5/9.5         | 83.9/16.1        | 1/0.55              | .063    |
| TT + AT/AA       | 95.3/4.7         | 87/13            | 1/0.33              | .0056   |
| TT + AA/AT       | 95.3/4.7         | 96.9/3.1         | 1/1.56              | .43     |
| A                | 7                | 15               | 2.0242              | .002    |
| T                | 93               | 85               | 0.92                |         |
| Gene/SNP/Alleles       | Activity       | Odds ratio (95% CI) | P value |
|-----------------------|----------------|---------------------|---------|
|                       | Yes (n=223)    | No (n=27)           |         |
| TLR4 (rs11536889)     |                |                     |         |
| GG/GC/CC              | 79.9/19.6/0.5  | 85.2/14.8/0         | 1/1.41/NA | .73   |
| GG/GC + CC            | 79.9/20.1      | 85.2/14.8           | 1/1.45   | .5    |
| GG + GC/CC            | 99.5/5         | 100/0               | 1/NA     | .63   |
| GG + CC/GC            | 80.4/19.6      | 85.2/14.8           | 1/1.4    | .54   |
| TLR4 (rs4986790)      |                |                     |         |
| AA/AG                 | 98.1/1.9       | 100/0               | 1/NA     | .3    |
| TLR 4 (rs200109652)   |                |                     |         |
| CC                    | 100            | 100                 | NA       | NA    |
| TLR4 (rs10759932)     |                |                     |         |
| TT/TC/CC              | 76.5/18/5.5    | 72/24/4             | 1/0.71/1.29 | .76 |
| TT/TC + CC            | 76.5/23.5      | 72/28               | 1/0.79   | .63   |
| TT + TC/CC            | 94.5/5.5       | 96/4                | 1/0.74   | .74   |
| TT + CC/TC            | 82/18          | 76/24               | 1/0.7    | .48   |
| TLR5 (rs5744174)      |                |                     |         |
| GG/GA/AA              | 30.5/62.4/7.1  | 25/75/0             | 1/0.68/NA | .14  |
| GG/GA + AA            | 30.5/69.5      | 25/75               | 1/0.79   | .58   |
| GG + GA/AA            | 92.9/7.1       | NA                  | 1/NA     | .068  |
| GG + AA/GA            | 37.6/62.4      | 25/75               | 1/0.55   | .21   |
| TLR5 (rs2072493)      |                |                     |         |
| TT/TC/CC              | 80/18.3/1      | 84/16/0             | 1/0.19/NA | .75  |
| TT/TC + CC            | 80.7/19.3      | 84/16               | 1/0.125  | .669  |
| TT + TC/CC            | 99/1           | 100/0               | 1/NA     | .48   |
| TT + CC/TC            | 81.7/18.3      | 84/16               | 1/0.17   | .79   |
| TLR5 (rs746250566)    |                |                     |         |
| GG                    | 100            | 100                 | NA       | NA    |
| TLR10 (rs559182335)   |                |                     |         |
| TT                    | 100            | 100                 | NA       | NA    |
| TLR10 (rs10004195)    |                |                     |         |
| TT/AT/AA              | 91.5/4.8/3.6   | 81.8/4.5/13.6       | 1/0.94/.23 | .2   |
| TT/AT + AA            | 91.8/8.3       | 81.8/18.2           | 1/0.41   | .18   |
| TT + AT/AA            | 96.4/3.6       | 86.4/13.6           | 1/0.23   | .075  |
| TT + AA/AT            | 95.2/4.7       | 95.5/4.5            | 1/1.05   | .96   |
Table 5. The effect of genotype distribution of single nucleotide polymorphisms on the severity of \textit{H pylori} infection in patients.

| Gene/SNP/Alleles          | Mild (n=67) | Moderate (n=113) | Severe (n=43) | P value |
|---------------------------|-------------|------------------|---------------|---------|
| TLR4 (rs11536889)         |             |                  |               |         |
| GG                       | 54 (25.2)   | 83 (38.8)        | 34 (15.9)     |         |
| GC                       | 7 (3.3)     | 29 (13.6)        | 6 (2.8)       | .053    |
| CC                       | 1 (0.5)     | 0 (0)            | 0 (0)         |         |
| G                        | 115 (26.9)  | 195 (45.6)       | 80 (18.7)     |         |
| C                        | 9 (2.1)     | 29 (12.9)        | 0 (0)         | .001    |
| TLR4 (rs4986790)          |             |                  |               |         |
| AG                       | 1 (0.5)     | 1 (0.5)          | 2 (1.0)       | .31     |
| GG                       | 58 (28.2)   | 107 (51.9)       | 37 (18)       | .31     |
| G                        | 1 (0.2)     | 1 (0.2)          | 2 (0.4)       |         |
| A                        | 117 (28.4)  | 215 (52.2)       | 76 (18.4)     | .31     |
| TLR4 (rs200109652)        |             |                  |               | NA      |
| CC                       | 67 (30.0)   | 113 (50.7)       | 43 (19.3)     | NA      |
| C                        | 134 (30.0)  | 226 (50.7)       | 86 (19.3)     | NA      |
| TLR4 (rs10759932)         |             |                  |               |         |
| TT                       | 41 (20.5)   | 84 (42.0)        | 28 (14)       | .63     |
| TC                       | 13 (6.5)    | 16 (8.0)         | 7 (3.5)       | .63     |
| CC                       | 4 (2.0)     | 4 (2.0)          | 3 (1.5)       |         |
| T                        | 95 (23.8)   | 184 (46.0)       | 63 (20.0)     | .22     |
| C                        | 21 (5.3)    | 24 (6.0)         | 13 (3.3)      |         |
| TLR5 (rs5744174)          |             |                  |               |         |
| GG                       | 3 (1.5)     | 6 (3.0)          | 5 (2.5)       | .09     |
| AG                       | 43 (21.8)   | 58 (29.4)        | 22 (11.2)     | .09     |
| AA                       | 12 (6.1)    | 38 (19.3)        | 10 (5.1)      |         |
| A                        | 67 (17.0)   | 134 (34.0)       | 42 (10.7)     | .24     |
| G                        | 49 (12.4)   | 70 (17.8)        | 32 (8.1)      |         |
| TLR5 (rs2072493)          |             |                  |               |         |
| TT                       | 46 (23.4)   | 86 (43.7)        | 27 (13.7)     | .07     |
| TC                       | 9 (4.6)     | 14 (7.1)         | 13 (6.6)      |         |
| CC                       | 0 (0)       | 2 (1.0)          | 0 (0)         |         |
| T                        | 101 (25.6)  | 186 (47.2)       | 67 (17)       | .13     |
| C                        | 9 (2.3)     | 18 (4.6)         | 13 (3.3)      |         |
be harmed by *H pylori* with the TLR4 polymorphisms. In agreement with Meliţ et al, we found no association between TLR4 variants (rs4986790 and rs4986791) and *H pylori* infection, which was inconsistent with many previous studies. Additionally, a northern Indian study illustrated that TLR4 rs4986791 is associated with a higher risk for plasma cell infiltration, which leads to atrophy and intestinal metaplasia. The rs4986790 GG genotype may functionally reduce the TLR4 binding affinity to *H pylori* LPS, resulting in a weakened adaptive immune response compared to the wild TLR4 type, which may vary by population.

The TLR10 showed considerable association in the rs10004195 (T>A) variant. The A allele frequency in the patients (7%) is around half of controls (15%). As a result, the A allele could have protective characteristics against the *H pylori* infection. The heterodimers formed from TLR10 that are expressed on the surface of gastric epithelial cells with TLR2 and/or TLR6 recognize multiple distinct patterns of *H pylori* LPS. TLR10 (rs10004195) is linked with infection susceptibility, where the frequency of the TT genotype is reported to be 66% in *H pylori*-positive cases from a Chinese population. Therefore, the T allele of TLR10 rs10004195 polymorphism showed an increased risk of chronic atrophic gastritis.

Significant linkage of the TLR5/rs744174 implies that the AA genotype could decrease the risk of PUD development due to *H pylori* infection, a finding consistent with a case-control study that examined TLR5 variants with *H pylori* infection in Chinese patients who have gastric cancer. Among the studied variants, rs5744174 (P=.001) is associated with gastric cancer susceptibility, indicating that TLR5 variants can impact the role of *H pylori* infection in gastric cancer formation. On the other hand, rs5744174 was not a risk factor for chronic *H pylori* in the population of Indian Tamils, where rs2072493 conferred resistance to the infection.

In summary, different host cytokine responses to the gastric mucosal inflammation induced by *H pylori* appear to produce a significant role in the clinical outcome, such as the development of gastric diseases and gastric cancer. However, the correlation between polymorphisms of host cytokine genes and the susceptibility to *H pylori* infection and severity of the clinical outcome has not been investigated thoroughly. Genetic heterogeneity as a result of ethnic diversity is a vital factor in the variation of allele frequency for several markers; hence, genetic heterogeneity affects the susceptibility and severity of the infection.

Ultimately, rs10004195/TLR10 and rs5744174/TLR5 variants appear to be genetic risk factors for *H pylori* infection and severity in the Jordanian population. Our findings further support the evidence of TLR polymorphisms as physiopathological actors in susceptibility to *H pylori* infection and related gastric problems. This type of genetic susceptibility could help in classifying patients based on their genetic profile and matching patients with various treatment options on a genetic basis.

### Table 5 (cont.). The effect of genotype distribution of single nucleotide polymorphisms on the severity of *H pylori* infection in patients.

| Gene/SNP/Alleles | Severity | P value* |
|------------------|----------|----------|
|                  | Mild (n=67) | Moderate (n=113) | Severe (n=43) |
| TLR5 (rs746250566) |       |          |        |
| GG               | 67 (30.0) | 113 (50.7) | 43 (19.3) |         |
| G                | 134 (30.0) | 226 (50.7) | 86 (19.3) |         |
| TLR5 (rs559182335) |       |          |        |
| TT               | 65 (26.3) | 113 (45.7) | 42 (17.0) |         |
| T                | 130 (26.3) | 226 (45.7) | 84 (19.1) |         |
| TLR10 (rs10004195) |       |          |        |
| TT               | 49 (29.2) | 78 (46.4)  | 27 (16.1) | .062    |
| AT               | 1 (0.6)  | 7 (4.2)   | 2 (1.2)  |         |
| AA               | 1 (0.6)  | 2 (1.2)   | 3 (1.5)  |         |
| T                | 99 (29.5)| 163 (48.5) | 56 (16.1) | .18     |
| A                | 3 (0.9)  | 11 (3.3)  | 6 (1.8)  |         |
H PYLORI INFECTION

Author contributions

LNA-E, FAA designed the study. LNA-E, FAA AND SMA-K were responsible for sample, demographic and clinical data collection. LNA-E, FAA, SMAA, RAA and MAA analyzed the sample and interpreted the data. LNA-E prepared the manuscript. All authors helped in reviewing the manuscript.

REFERENCES

1. Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med. 1991 Oct;325(16):1127-31.

2. Wang K, Wang R. Meta-analysis on the epidemiology of Helicobacter pylori infection in China. Europe PMC. 2003 Jun 1;24(6):443-6.

3. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer. 2006 Jun 15;118(12):1600-4.

4. Goudarzi H, Seyedi-Jawadi S, Fazeli M, Azad M, Goudarzi M. Genotyping of peroxisome proliferator-activated receptor gamma in iranian patients with Helicobacter pylori infection. Asian Pacific J Cancer Prev. 2015;16:5219-23.

5. Wang P, Zhang L, Jiang JM, Ma D, Tao HX, Yuan, et al. Association of NOD1 and NOD2 genes polymorphisms with Helicobacter pylori related gastric cancer in a Chinese population. World J Gastroenterol: WJG. 2012 May 7;18(17):2112-20.

6. Wong F, Rayner-Hartley E, Byrne MF. Extraintestinal manifestations of Helicobacter pylori: A concise review. World J Gastroenterol: WJG. 2014 Sep 14;20(34):11950-61.

7. Kalkanli Tas S, Kirkik D, Tanoglu A, Kahraman R, et al. Vacuolating cytotoxin and variants in Atg16L1 that dissociate the presence of Helicobacter pylori-induced premalignant gastric lesions and gastric cancer in Caucasians. BMC Med Genet. 2011 Dec 1;12(1):112.

8. Melit LE, Marginean CO, B?nescu C, Bog?i A, Mocan S, Ianca M. The relationship between TLRA n4986790 and n4986791 gene polymorphisms and Helicobacter pylori infection in children with gastritis. Pathol Res Pract. 2019 Dec;121(12):152692.

9. Achiut BR, Ghoshal UC, Moorchung M?rginean, MO. The relationship between toll-like receptors and Helicobacter pylori- related gastropathies: still a controversial topic. J Immunol. Res. 2019 Oct;2019.

10. Eed EM, Hawashi YA, Khalifa AS, Alsharif KF, Alghamdi SA, Almalki AA, et al. Association of toll-like receptors 2, 4, 9 and 10 genes polymorphisms and Helicobacter pylori-related gastrointestinal diseases in Saudi patients. Indian J Med Microbiol. 2011 Jul;1;38(1):94-100.

11. Lee YC, Chen TH, Chiu HM, Shun CT, Chiang H, Liu TY. The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention. Gut. 2013 May 1;62(5):676-82.

12. Román-Román A, Martínez-Carrillo DO, Atrisco-Morales J, Auzair-Hezqiu JC, Cueva-Caballero AS, Castañón-Sánchez CA, et al. Helicobacter pylori vacA s1m1 genotype but not cagA or baba2 increase the risk of ulcer and gastric cancer in patients from Southern Mexico. Gut Pathog. 2017 Dec 1;9(1):18.

13. Kalkanli Tas S, Kirlik D, Tanoglu A, Kahraman R, Oztunk K, Eser MF, et al. Polymorphisms in Toll-like receptors 1, 2, 5, and 10 are associated with predisposition to Helicobacter pylori infection. Eur J Gastroenterol Hepatol. 2020 Mar 13;32(9):1141-6.

14. Nagashima H, Iwatsuki S, Cruz M Nagashima H, Iwatsuki S, Cruz M, Jiménez Abreu JA, Uchida T, Mahachai V, et al. Toll-like Receptor 10 in Helicobacter pylori infection. J Infect Dis. 2015 Nov;12;5(12):1666-76.

15. Stolte M, Meining A. The updated Sydney system Classification and grading of gastritis as the basis of diagnosis and treatment. Can J Gastroenterol. 2001 Sep 1;15(9):591-98.

16. Jensen PJ, Feldman M, LaMont JT, Gross J. Acute and chronic gastritis due to Helicobacter pylori. Up to date. 2019.

17. Velin D, Straubinger K, Gerhard M. Inflammation, immunity, and viruses for Helicobacter infection. Helicobacter. 2016 Sep;21:26-9.

18. Kupcinets J, Wex T, Bornschein J, Seglad M, Leja M, Juzaíyte E, et al. Lack of association between gene polymorphisms of Angiotensin converting enzyme, Nod like receptor 1, Toll-like receptor 4, FAS/FASL and the presence of Helicobacter pylori-induced premalignant gastric lesions and gastric cancer in Caucasians. BMC Med Genet. 2011 Dec 1;12(1):112.

19. Sonnenberg A, Bartpho T, Kaewpitoon S, Kaewpitoon N, Dechsukhum C, Leeansaksiri W, et al. Genetic polymorphisms in TLRA, TLRB, TLRC, and TLRD of Helicobacter pylori-associated gastriitis: a prospective cross-sectional study in Thailand. Eur J Cancer Prev. 2018 Mar;27(2):118-23.

20. Xu T, Fu D, Ren Y, Dai Y, Lin J, Tang L, Li J. Genetic variations of TLRS gene interacted with Helicobacter pylori infection among carcinogenesis of gastric cancer. Oncotarget. 2017 May;8(19):31016-31022.

21. Goda V, Jayaraman M, Loganathan R, Nazeer M, Ali M, Karunakaran P, Desai MM, et al. TLRS polymorphisms rs292493, rs744174, and rs744168 are not genetic risk factors for chronic Helicobacter pylori infection in Indian Tamils. Immunol Invest. 2017 Aug;46(6):537-543.

22. Varga MG, Piazeblo MB, Romero-Gallo J, Delgado AG, Suarez G, Whitaker ME, et al. TL9R activation suppresses inflammation in response to Helicobacter pylori infection. Am J Physiol - Gastrointest Liver Physiol. 2016 Nov 13;315(5):G852-8.

23. Moura SB, Almeida LR, Guerra JB, Rocha GA, Rocha AM, Melo FF, et al. Toll-like receptor (TLR2, TLR4 and TLR5) gene polymorphisms and Helicobacter pylori infection in children with and without duodenal ulcer. Microbes Infect. 2008 Nov 1;10(14-15):1477-83.

24. Han R, Lu H, Jiang MW, Tan KW, Peng Z, Hu JL, et al. Multicenter Study of Antibiotic Resistance Profile of H pylori and Distribution of CYP2C19 Gene Polymorphism in Rural Population of Chongqing, China. Gastroenterol Res Pract. 2016 Oct;16.